SI-BONE outlines 18%–20% revenue growth target for 2025 with platform expansion, eyes positive free cash flow in 2026

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Full year revenue guidance updated to range between $198 million to $200 million, implying year-over-year growth of approximately 18% to 20% compared to previous guidance of approximately 17% to 18%

  80% confidence

• NTAP became effective October 1 at around $4,100, representing up to 30% improvement in reimbursement

  80% confidence

• Worldwide revenue was $48.7 million in Q3 2025, representing growth of 20.6%, with U.S. revenue of $46.4 million representing 21.2% growth driven by procedure volume growth of over 22%

  80% confidence

• SI-BONE was breakeven on a net cash flow basis and ended the quarter with $145.7 million in cash and marketable securities while generating $2.3 million cash from operating activities

  80% confidence

• Over the medium term, gross margins expected to stabilize around 78%, 78.5% area

  80% confidence

• Procedures using more than 2 Granite implants per case grew approximately 40% in the quarter

  80% confidence

• Full year gross margin expected to be at 79.5%, with annual operating expense growth guidance maintained at 10% at the midpoint of the revenue range

  80% confidence

• Operating leverage tracking to about 1.9x at the midpoint of revenue and OpEx growth guidance for the year

  80% confidence

• Only around 25% of SI joint surgeons are currently performing another procedure type, representing significant opportunity to increase physician density

  80% confidence

• Average selling price was quite stable with good traction in Granite, especially with multiple implant cases

  80% confidence

• SI-BONE is confident in ability to sustain strong top line growth, expand margins and inflect on free cash flow going into 2026

  80% confidence

• Gross profit was $38.8 million, an increase of $6.9 million or 21.8%, with gross margin of 79.8%, expanding by 75 basis points year-over-year

  80% confidence

• SI-BONE anticipates launching next-generation technology product in the first quarter of 2026

  80% confidence

• CMS proposed 17% reimbursement increase for office-based SI joint fusion procedures represents additive opportunity with interventionalists

  80% confidence

• SI-BONE feels comfortable with where the current consensus is for 2026 revenue expectations

  80% confidence

• The second product launching in 2026 will have a significant impact on growing the total addressable market even further

  80% confidence

• SI-BONE achieved another quarter of robust revenue growth, sustained adjusted EBITDA profitability and reached a major milestone in delivering positive operating cash flow

  80% confidence

• SI-BONE expects to use a little bit of cash in Q4 due to building up surgical capacity and capacity for new product

  80% confidence

• Operating leverage should be a little bit on the lower end in 2026, increasing as new products ramp

  80% confidence

• SI-BONE had 88 territory managers as of the end of Q3 and wants to get to 100 territories over the next 12 to 18 months

  80% confidence

• Interventional case volume doubled compared to Q3 2024 as physicians recognize the value of clinically validated solutions

  80% confidence

• Net loss narrowed to $4.6 million or $0.11 per diluted share compared to a net loss of $6.6 million or $0.16 per diluted share, with positive adjusted EBITDA of $2.3 million for the quarter translating to adjusted EBITDA margin of approximately 5%

  80% confidence